Who Paid My Doc
Adynovate
Biological Hematology
NDC 0944-4252-02
General payments
$192,921
Research payments
$1,495,143
Through program year 2025, $192,921 in general payments and $1,495,143 in research payments were reported against Adynovate (Hematology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $26,928 | 29 |
| 2025 | Research | $186,111 | 51 |
| 2024 | General | $7,303 | 21 |
| 2024 | Research | $44,135 | 1 |
| 2023 | General | $4,695 | 18 |
| 2023 | Research | $286,210 | 38 |
| 2022 | General | $4,582 | 16 |
| 2022 | Research | $136,219 | 37 |
| 2021 | General | $72,629 | 54 |
| 2021 | Research | $89,514 | 69 |
| 2020 | General | $28,797 | 72 |
| 2020 | Research | $276,166 | 129 |
| 2019 | General | $47,987 | 200 |
| 2019 | Research | $476,788 | 272 |
Breakdown
The top 5 of 15 recipients; each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 9 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
410 general · 597 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.